Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize TPM-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist
PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today......